Humacyte, Inc. (HUMA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$48.9M
Cash & Equivalents
$25.1M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$187M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-06-01 | Phase3 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT03005418 | Humacyte Human Acellular Vessel (HAV) in Patients With Vascular Trauma | PHASE3 | Active Not Recruiting | 72 |
| NCT05908084 | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi... | PHASE3 | Active Not Recruiting | 121 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.